Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Most Medical Institutions Leery of Generics Despite Increased Use
January 8, 2007
- Shionogi, DSP to Enter ARB Market with Irbesartan
January 8, 2007
- Generic Entry Should Be Permitted in the Absence of Original Products: Ihoken
January 8, 2007
- Sales to Break \80 Bil. in 2006: Schering-Plough
January 8, 2007
- GENERIC NEWS IN BRIEF
January 8, 2007
- Teijin to Invest in New Businesses Including Healthcare
January 8, 2007
- MEDICAL DEVICE NEWS IN BRIEF
January 8, 2007
- BUSINESS NEWS IN BRIEF
January 8, 2007
- Hospitals to Demand that Insurers Pay Unpaid Copayments
January 8, 2007
- JPLA Seminae
January 8, 2007
- J&J Extends Its SOHO Day System to Include Employees with School Children
January 8, 2007
- UtoBrain Seminae
January 8, 2007
- AstraZeneca to Simultaneously Start All PI Trials Worldwide
December 25, 2006
- SMO Group Holds CRC Training Seminar
December 25, 2006
- Sanofi-aventis to Start Large Epidemiological Study in Cerebral Infarction Patients
December 25, 2006
- Pazufloxacin Can Now Be Used as 1st-Choice Drug: Toyama, MPC
December 25, 2006
- Wyeth, Kyushu Univ. Moving Forward with Their R&D Alliance
December 25, 2006
- Chugai to Copromote Otsuka's Antiplatelet Agent Pletaal
December 25, 2006
- REGULATORY NEWS IN BRIEF
December 25, 2006
- Pfizer to Continue Launching Series of New Drugs: President Iwasaki
December 25, 2006
ページ
Japan will overhaul its R&D tax credit regime in its FY2026 reform, introducing a new strategic category alongside existing frameworks.…
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…